Bauer Steffen, Störmer Elke, Kerb Reinhold, Johne Andreas, Brockmöller Jürgen, Roots Ivar
Institute of Clinical Pharmacology, University Medical Centre Charité, Humboldt University of Berlin, Schumannstrasse 20/21, 10098 Berlin, Germany.
Eur J Clin Pharmacol. 2002 Dec;58(9):581-5. doi: 10.1007/s00228-002-0527-5. Epub 2002 Nov 12.
We investigated the effects of treatment with Saint John's wort (hypericum perforatum) extract on the urinary excretion of D-glucaric acid, 6beta-hydroxycortisol, and free cortisol in order to assess the effect of this extract on the activity of hepatic xenobiotic metabolizing enzymes.
Forty-eight healthy volunteers (25 male and 23 female) received a daily dose of 1800 mg hypericum extract for 14 days. Urinary excretion of D-glucaric acid, 6beta-hydroxycortisol, and free cortisol was measured in 24-h urine samples on the day preceding the initiation of hypericum treatment and after 14 days of treatment. D-Glucaric acid was measured enzymatically. Cortisol and 6beta-hydroxycortisol were quantified using high-performance liquid chromatography with ultraviolet detection.
Urinary excretion of D-glucaric acid was unaffected after a 14-day treatment with Saint John's wort extract (26.7 micromol/day vs 27.7 micromol/day; 95% confidence interval of the difference: -1.9 to 3.8). The urinary excretion of 6beta-hydroxycortisol increased from a mean baseline value of 254 microg/day to 369 microg/day (P<0.0001) indicating induction of CYP3A. While the excretion of free cortisol was unaltered, the ratio of 6beta-hydroxycortisol to free cortisol changed significantly from 9.9 at baseline to 14.3 (95% confidence interval of the difference: 2.3-6.5) after Saint John's wort treatment.
High-dose treatment with Saint John's wort extract induced CYP3A activity in healthy volunteers as evidenced by increased 6beta-hydroxycortisol excretion. This enzyme induction most likely contributes to the decreased bioavailability observed upon co-administration of various drugs with Saint John's wort extract. The D-glucuronic acid pathway appeared unaffected by Saint John's wort.
我们研究了圣约翰草提取物治疗对D - 葡糖醛酸、6β - 羟基皮质醇和游离皮质醇尿排泄的影响,以评估该提取物对肝脏异生物质代谢酶活性的作用。
48名健康志愿者(25名男性和23名女性)连续14天每日服用1800毫克圣约翰草提取物。在开始圣约翰草治疗前一天以及治疗14天后,测量24小时尿液样本中D - 葡糖醛酸、6β -羟基皮质醇和游离皮质醇的尿排泄量。D - 葡糖醛酸采用酶法测定。皮质醇和6β - 羟基皮质醇使用带紫外检测的高效液相色谱法定量。
经14天圣约翰草提取物治疗后,D - 葡糖醛酸的尿排泄量未受影响(26.7微摩尔/天对27.7微摩尔/天;差异的95%置信区间:-1.9至3.8)。6β - 羟基皮质醇的尿排泄量从平均基线值254微克/天增加到369微克/天(P<0.0001),表明CYP3A被诱导。虽然游离皮质醇的排泄未改变,但圣约翰草治疗后,6β - 羟基皮质醇与游离皮质醇的比值从基线时的9.9显著变为14.3(差异的95%置信区间:2.3 - 6.5)。
高剂量圣约翰草提取物治疗可诱导健康志愿者的CYP3A活性,6β - 羟基皮质醇排泄增加证明了这一点。这种酶诱导很可能是多种药物与圣约翰草提取物合用时观察到的生物利用度降低的原因。D - 葡糖醛酸途径似乎未受圣约翰草影响。